Mode
Text Size
Log in / Sign up
N/A N=50 Treatment

Effectiveness and Safety of the Octave System for Lifting the Eyebrow and Improving the Appearance of the Face and Neck

Eyebrow Lift · Improved Appearance of the Face and Neck

Enrolled (actual)
50
Serious AEs
2.0%
Results posted
Oct 2025
Primary outcome: Primary: Percentage of Treated Subjects With Eyebrow Lift at Day 90 — 80.0; 67.5 percentage of subjects

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Octave-Ultherapy treatment (Device)
Age
Adult, Older Adult · 35+ yrs
Sex
All
Sponsor
Merz North America, Inc.
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Treated Subjects With Eyebrow Lift at Day 90
80.0; 67.5
SECONDARY
Percentage of Treated Subjects With Eyebrow Lift at Day 180
81.7; 64.7
SECONDARY
Percentage of Treated Subjects With Eyebrow Lift of at Least 0.5 Millimeter (mm) at Day 90 and Day 180
20.0; 27.5; 16.7; 30.8
SECONDARY
Change From Baseline in FACE-Q Satisfaction With Forehead and Eyebrows Score (Rasch-transformed) at Day 90 and Day 180, as Assessed by Subject
10.1; 21.1; 20.5; 22.7
SECONDARY
Change From Baseline in FACE-Q Satisfaction With Lower Face and Jawline Score (Rasch-transformed) at Day 90 and Day 180, as Assessed by Subject
25.0; 28.9; 37.2; 26.9
SECONDARY
Change From Baseline in FACE-Q Patient-Perceived Age Visual Analogue Scale (VAS) Rating at Day 90 and Day 180, as Assessed by the Subject
-0.9; -2.2; -2.0; -2.4
SECONDARY
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Related to Octave-Ultherapy Treatment
4; 6

Summary

This study was conducted to evaluate the effectiveness and safety of the Octave System to lift the eyebrow and improve the appearance of the face and neck.

Eligibility Criteria

Inclusion Criteria

  • Mild to moderate eyebrow/upper-face laxity.
  • Mild to moderate fine lines, wrinkles, and laxity of the face and neck.

Exclusion Criteria

  • Presence of an active systemic or local skin disease that may affect wound healing.
  • Scarring in area(s) to be treated.
  • Active implants (e.g., pacemakers or defibrillators), ports, or metallic implants in area(s) to be treated.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05067504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search